Nuri Telecom Company Limited Announces Compulsory Acquisition of Remaining Apivio Shares

VANCOUVER, BC—(Marketwired – June 13, 2017) – Nuri Telecom Company Limited (“Nuri“) announced today that, following the take–up and payment of 49,866,773 common shares (“Apivio Shares“) of Apivio Systems Inc. (“Apivio“) pursuant to the previously announced takeover offer (the “Offer“) by Nuri's wholly–owned subsidiary 1101324 B.C. Ltd. (the “Offeror“), the Offeror has today mailed a notice of compulsory acquisition (the “Notice of Compulsory Acquisition“) to all remaining holders of Apivio Shares in accordance with the compulsory acquisition provisions in the Business Corporations Act (British Columbia) (“BCBCA“) (the “Compulsory Acquisition“).

Under the terms of the Compulsory Acquisition, and subject to the terms of the BCBCA, the holders of all the remaining Apivio Shares not currently owned by the Offeror (“Remaining Shareholders“) will be entitled to receive the same consideration per share as paid under the Offer, being $0.45 in cash per share. Further details are provided in the Notice of Compulsory Acquisition, filed under the Apivio profile on SEDAR at

In order to receive payment for their shares, Remaining Shareholders must submit the letter of transmittal circulated with the Notice of Compulsory Acquisition along with all certificates representing their shares to Laurel Hill Advisory Group. The Offeror intends to pay the cash consideration for the remaining Apivio Shares on or about August 15, 2017. Remaining Shareholders are requested to complete and return the letter of transmittal before August 14, 2017.

Apivio Shares are expected to be delisted from the TSX Venture Exchange on or about June 16, 2017.

Shareholder Questions

If Remaining Shareholders have any questions regarding the Notice of Compulsory Acquisition or require assistance with depositing Remaining Shares, please call the Depositary, Laurel Hill Advisory Group , toll free in North America at 1–877–452–7184 (+1–416–304–0211 outside North America), or by email at

Advisors to the Offeror

The Offeror has engaged PI Financial Corp. to act as its financial advisor. Norton Rose Fulbright Canada LLP is acting as the legal advisor in connection with the Compulsory Acquisition.

Laurel Hill Advisory Group has been retained as Depositary for the Compulsory Acquisition. Remaining Shareholders may contact Laurel Hill Advisory Group by telephone at 1–877–452–7184 (Toll Free in North America) or 1–416–304–0211 (Collect Outside North America) or by email at

About Nuri

Nuri is a provider of next generation communication technology for the Internet of Things (“IoT“) and the Smart Grid industry. Nuri is a global leader in providing end–to–end advanced metering infrastructure solutions that save consumers money and help utilities to run a network infrastructure that's proven, reliable, future–proof and fully standardized. Nuri's core product offering is a communication solution for smart meters, AiMiR, which provides automatic meter readings of electricity, water, gas and other measurements and delivers gathered data through a variety of networks in real time. AiMiR helps consumers and utility companies manage their resource consumption by providing real time information, accommodating their resource distribution to optimum levels for both short term and long term infrastructure needs.

To date, Nuri has deployed its communication systems to over two million households and businesses in 19 countries worldwide, and that number continues to grow each day through large–scale deployments in commercial, industrial, and residential markets. With a growing list of global customers, Nuri is expanding its customer base throughout Asia, Europe and Africa. Recently, Nuri has won US$79 million Soria projects in Norway and US$12 million ECG projects in Ghana.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

This news release does not constitute an offer to buy or the solicitation of an offer to sell any of the securities of the Offeror, Nuri or Apivio.

Forward–Looking Information Cautionary Statement

This news release contains certain forward–looking information (referred to herein as “forward–looking statements“). Forward–looking statements are often, but not always, identified by the use of words such as “anticipate”, “believe”, “plan”, “scheduled”, “intend”, “objective”, “continuous”, “ongoing”, “estimate”, “expect”, “may”, “will”, “project”, “should”, or similar words suggesting future events, circumstances or outcomes. In particular, this news release contains forward–looking information concerning the payment for Remaining Shares deposited under the Notice of Compulsory Acquisition, including the timing thereof, and the delisting of Apivio Shares from the TSX Venture Exchange.

Forward–looking statements are based upon the opinions and expectations of management of Nuri as at the effective date of such statements. Although Nuri believes the expectations reflected in such forward–looking statements are based upon reasonable assumptions, it can give no assurance that those expectations will prove to have been correct. Forward–looking statements are subject to certain risks and uncertainties that could cause actual events or outcomes to differ materially from those anticipated or implied by such forward–looking statements. These risks and uncertainties include, but are not limited to, such things as changes in general economic conditions in Canada and elsewhere and new laws and regulations (domestic and foreign).

Having regard to the various risk factors, readers should not place undue reliance upon the forward–looking statements contained in this news release and such forward–looking statements should not be interpreted or regarded as guarantees of future outcomes.

The forward–looking statements contained in this news release are made as of the date hereof and Nuri does not undertake any obligation to update or to revise any of the included forward–looking statements, except as required by applicable securities laws in force in Canada. The forward–looking statements contained in this news release are expressly qualified by this cautionary statement.

Agrium Announces Acquisition of Starpharma's Agrochemical Polymer Technology Business

CALGARY, AB—(Marketwired – June 13, 2017) – Agrium Inc. (TSX: AGU) (NYSE: AGU), through its subsidiary Loveland Products, Inc. announced today that it has closed on the acquisition of Starpharma Holdings Limited's agrochemical business focused on development of its proprietary Priostar® dendrimer polymer technology portfolio for $35 million. The acquisition is comprised of key intellectual property, as well as a small number of dedicated staff based in Melbourne, Australia. These assets will support Agrium's innovation and technology strategy through the ability to continue providing unique proprietary products that address existing and emerging grower challenges.

This acquisition will lay the foundation for the continued development and commercialization of the Priostar® dendrimer polymer technology across a broad base of Loveland Products' crop protection and specialty nutrition products, improving product performance and further enhancing Agrium Retail's full solutions offering to growers. This technology has proven to provide numerous benefits including better weed control capabilities, formulation stability and reduced environmental impacts.

“This acquisition represents an exciting strategic technology platform for Loveland Products that will serve to further differentiate our proprietary product line and open new product development partnership opportunities. Agrium is uniquely positioned to commercialize this technology across our 1,500 ag–retail centers, which service hundreds of thousands of growers in key agricultural markets globally,” said Chuck Magro, President & CEO of Agrium.

About Agrium

Agrium Inc. is a major global producer and distributor of agricultural products, services and solutions. Agrium produces nitrogen, potash and phosphate fertilizers, with a combined wholesale nutrient capacity of over nine million tonnes and with significant competitive advantages across our product lines. We supply key products and services directly to growers, including crop nutrients, crop protection, seed, as well as agronomic and application services, thereby helping growers to meet the ever growing global demand for food and fibre. Agrium retail–distribution has an unmatched network of over 1,500 facilities and over 3,800 crop consultants who provide advice and products to our grower customers to help them increase their yields and returns on hundreds of different crops. With a focus on sustainability, the company strives to improve the communities in which it operates through safety, education, environmental improvement and new technologies such as the development of precision agriculture and controlled release nutrient products. Agrium is focused on driving operational excellence across our businesses, pursuing value–enhancing growth opportunities and returning capital to shareholders. For more information visit:

About Loveland Products, Inc.

Loveland Products, Inc. offers a complete line of high–performance input products to the global agricultural and professional non–crop industries. Loveland Products' diversified portfolio of premium products consists of seed treatment, plant nutrition, fertilizer, adjuvant and crop protection products, which are available through Agrium Retail in North America, South America and Australia, and through distribution partners in over 40 countries globally. Loveland Products strives to bring new, unique products and technologies to the marketplace to provide innovative solutions to problems across the agricultural and professional non–crop industries. For more information visit:

About Starpharma Holdings Limited

Starpharma Holdings Limited, located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications. Starpharma's underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical and medical uses. Starpharma has two core development programs: VivaGel® portfolio and DEP® drug delivery with the Company developing a number of products internally and others via commercial partnerships. For more information visit:

Forward‐Looking Statements

Certain statements and other information included in this press release constitute “forward‐looking information” or “forward‐looking statements” (collectively, “forward‐looking statements”) under applicable securities laws. All statements in this press release, other than those relating to historical information or current conditions, are forward‐looking statements, including, but not limited to, statements as to management's expectations with respect to: the transaction with Starpharma, including the new company's assets and growth prospects; the anticipated benefits of the transaction, including strategic opportunities; and certain combined operational and other information.

Forward‐looking statements in this press release are based on certain key expectations and assumptions made by Agrium, including expectations and assumptions concerning: customer demand for the unique proprietary products; commodity prices and interest and foreign exchange rates; planned synergies, capital efficiencies and cost‐savings; applicable tax laws; the sufficiency of budgeted capital expenditures in carrying out planned activities; and the availability and cost of labour and services. Although Agrium believes that the expectations and assumptions on which such forward‐looking statements are based are reasonable, undue reliance should not be placed on the forward‐looking statements because Agrium can give no assurance that they will prove to be correct.

Forward–looking statements are subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this press release. The key risks and uncertainties include, but are not limited to: general global economic, market and business conditions; weather conditions including impacts from regional flooding and/or drought conditions; crop plant area, yield and prices; the supply and demand and price levels for major products of Agrium may vary from what we currently anticipate; governmental and regulatory requirements and actions by governmental authorities, including changes in government policy, government ownership requirements, changes in environmental, tax and other laws or regulations and the interpretation thereof, and political risks, including civil unrest, actions by armed groups or conflict, counterparty and sovereign risk; relationships with employees, customers, business partners, and competitors; and other risk factors detailed from time to time in Agrium's reports filed with Canadian securities regulators and the Securities and Exchange Commission in the U.S. including those disclosed under the heading “Risk Factors” in our Annual Information Form for the year ended December 31, 2016 and under the headings “Enterprise Risk Management” and “Key Assumptions and Risks in respect of Forward–Looking Statements” in our 2016 annual MD&A. There are also risks that are inherent in the nature of the transaction, including: failure to realize anticipated synergies or cost savings; risks regarding the integration of two companies; and incorrect assessments of the values of the other entity.

Agrium disclaims any intention or obligation to update or revise any forward–looking statements in this press release as a result of new information or future events, except as may be required under applicable U.S. federal securities laws or applicable Canadian securities legislation.

Additional Information and Where to Find It

Additional information about Agrium can be found under its corporate profile on SEDAR at or at, or by contacting the contacts below.